Shield Therapeutics’ (STX) “Corporate” Rating Reiterated at FinnCap
FinnCap restated their corporate rating on shares of Shield Therapeutics (LON:STX) in a research report sent to investors on Wednesday, ThisIsMoney.Co.Uk reports.
Separately, Peel Hunt reissued a buy rating on shares of Shield Therapeutics in a research note on Thursday, August 1st.
Shares of LON STX opened at GBX 170 ($2.22) on Wednesday. Shield Therapeutics has a twelve month low of GBX 27 ($0.35) and a twelve month high of GBX 202 ($2.64). The business’s fifty day moving average price is GBX 128.06. The company has a market capitalization of $199.22 million and a P/E ratio of -113.33.
Shield Therapeutics plc, a specialty pharmaceutical company, in the development and commercialization of hospital-focused pharmaceuticals to treat unmet medical needs. Its lead product is Feraccru, a novel therapy for the treatment of iron deficiency anemia in patients with inflammatory bowel disease.
Recommended Story: The Discount Rate – What You Need to Know
Receive News & Ratings for Shield Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shield Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.